Cargando…
Chemotherapy-Induced Nausea and Vomiting in Gastrointestinal Cancer Patients: Do We Need to Revisit Guidelines?
Purpose The objective of this study was to assess the proportion of patients developing chemotherapy-induced nausea and vomiting (CINV) after receiving chemotherapy for gastrointestinal (GI) cancers, despite receiving antiemetic prophylaxis (AEP) as per the standard guidelines. Patients and Methods...
Autores principales: | Kapoor, Akhil, Jain, Ashutosh, Sharma, Abhishek, Shah, Minit, Chinthala, Shravan, Nandhana, Ravindra, Bhargava, Prabhat, Ramaswamy, Anant, Srinivas, Sujay, Ostwal, Vikas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Thieme Medical and Scientific Publishers Private Ltd
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205558/ https://www.ncbi.nlm.nih.gov/pubmed/34141686 http://dx.doi.org/10.1055/s-0041-1729493 |
Ejemplares similares
-
Chemotherapy-Induced Nausea and Vomiting (CINV) with GI Cancer Chemotherapy: Do We Need CINV Risk Score Over and Above Antiemetic Guidelines in Prescribing Antiemetic Regime?
por: D’Souza, Anita, et al.
Publicado: (2020) -
Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis
por: Ramaswamy, Anant, et al.
Publicado: (2023) -
Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomas—A Relatively Rare Component of Biliary Tract Cancers in India
por: Bhargava, Prabhat G., et al.
Publicado: (2020) -
An Analysis of Tolerance and Early Survival Outcomes with Perioperative Modified FLOT in Gastric Cancers
por: Bhargava, Prabhat, et al.
Publicado: (2022) -
Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
por: Ramaswamy, Anant, et al.
Publicado: (2022)